Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer

Journal of Surgical Oncology

Volumn 82, Issue 2, 2003, Pages 84-90

  Petrik, David W ^a   McCready, David R ^b,c   Sawka, Carol A ^d,e   Goel, Vivek ^f,g  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Academic medical centers; Axilla; Breast neoplasms; Lymph node excision; Lymphatic metastases; Treatment outcome

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURGEON; SURGICAL TECHNIQUE; TEACHING HOSPITAL; TREATMENT OUTCOME;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; COHORT STUDIES; EPIDEMIOLOGIC FACTORS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; REGISTRIES; SURGERY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037308187     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10198     Document Type: Article

References (51)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA 2000;50:7-33.
2. National Cancer Institute of Canada: "Canadian Cancer Statistics 2000." Toronto, Canada: National Cancer Institute of Canada, 2000.
3. Iscoe NA, To T, Gort EH, Tran M: "Cancer Surgery in Ontario." Ontario, Canada: Institute for Clinical Evaluative Sciences, 1997.
4. Iscoe NA, Goel V, Wu K, et al.: Variation in breast cancer surgery in Ontario. Can Med Assoc J 1994;150:345-352.
5. Goel V, Olivotto I, Hislop TG, et al.: Patterns of initial management of node-negative breast cancer in two Canadian provinces. Can Med Assoc J 1997;156:25-35.
6. Petrik DW, McCready DR, Goel V, et al.: The use of different surgical strategies for early breast cancer in Ontario and their effect on breast conservation. Can J Surg 1999;42(suppl):117-118.
7. National Cancer Institute: "Breast Cancer (PDQ®) Treatment-Health Professionals. Stage I, II and IIIA Breast Cancer." Vol 2000. Toronto, Canada: National Cancer Institute, 2000.
8. Mirsky D, O'Brien SE, McCready DR, et al.: Surgical management of early stage invasive breast cancer (stage I and II). Cancer Prev Control 1997;1:10-17.
9. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Clinical practice guidelines for the care and treatment of breast cancer. Can Med Assoc J 1998; 158(suppl 3):S1-S83.
10. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
11. Goldhirsch A, Glick JH, Gelber RD, Senn H-J: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998;90:1601-1608.
12. Atkins H, Hayward JL, Klugman DJ, Wayte AB: Treatment of early breast cancer: A report after ten years of a clinical trial. BMJ 1972;2:423-4239.
13. Hayward J, Caleffi M: The significance of local control in the primary treatment of breast cancer. Arch Surg 1987;122:1244-1247.
14. Fisher B, Redmond C, Fisher ER, et al.: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-681.
15. Cabanes PA, Salmon RJ, Vilcoq JR, et al.: Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1992;339:1245-1248.
16. Orr RK: The impact of prophylactic axillary node dissection on breast cancer survival - A Bayesian meta-analysis. Ann Surg Oncol 1999;6:109-116.
17. Petrek JA, Blackwood MM: Axillary dissection: Current practice and technique. Curr Probl Surg 1995;32:257-323.
18. Ball ABS, Fish S, Waters R, Thomas JM: Radical axillary dissection in the staging and treatment of breast cancer. Ann R Coll Surg Eng 1992;74:126-129.
19. Haybittle JL, Blarney RW, Elston CW, et al.: A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-366.
20. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-219.
21. Rose CM, Botnick LE, Weinstein M, et al.: Axillary sampling in the definitive treatment of breast cancer by radiation therapy and lumpectomy. Int J Radiat Oncol Biol Phys 1983;9:339-344.
22. Steele RJC, Forrest APM, Gibson T, et al.: The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: A controlled randomized trial. Br J Surg 1985;72:368-369.
23. August DA, Sondak VK: Breast. In Greenfield LJ, Mulholland MW, Oldham KT, et al. (eds). "Surgery: Scientific Principles and Practice." Philadelphia: Lippincott-Raven, 1997:1357-1415.
24. Rosen PP, Lesser ML, Kinne DW, Beattie EJ: Discontinuous or "skip" metastases in breast carcinoma: Analysis of 1228 axillary dissections. Ann Surg 1983;197:276-283.
25. Van Lancker M, Goor C, Sacre R, et al.: Patterns of axillary lymph node metastasis in breast cancer. Am J Clin Oncol 1995;18:267-272.
26. Foster RS: Biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin North Am 1996;5:79-104.
27. Danforth DN Jr, Findlay PA, McDonald HD, et al.: Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986;4:655-662.
28. Axelsson CK, Mouridsen HT, Zedeler K, the Danish Breast Cancer Cooperative Group (DBCG): Axillary dissection of level I and level II lymph nodes is important in breast cancer classification. Eur J Cancer 1992;28A:1415-1418.
29. Mathiesen O, Carl J, Bonderup O, Panduro J: Axillary sampling and the risk of erroneous staging of breast cancer. Acta Oncol 1990;29:721-725.
30. Kissin MW, Thompson EM, Price AB, et al.: The inadequacy of axillary sampling in breast cancer. Lancet 1982;8283:1210-1211.
31. Fisher B, Wolmark N, Bauer M, et al.: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histological nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-772.
32. Graversen HP, Blichert-Toft M, Andersen JA, et al.: Breast cancer: Risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14:407-412.
33. Recht A, Houlihan MJ: Axillary lymph nodes and breast cancer: A review. Cancer 1995;76:1491-1512.
34. Rageth JC, Wyss P, Unger C, Haller U: Axillary lymphadenectomy-Just how radical should it be? Surg Oncol 1996;5:37-41.
35. Fisher B, Slack NH: Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970;131: 79-88.
36. Kjaergaard J, Blichert-Toft M, Andersen JA, et al.: Probability of false negative nodal staging in conjunction with partial dissection in breast cancer. Br J Surg 1985;72:365-367.
37. Sosa JA, Diener-West M, Gusev Y, et al.: Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140-149.
38. Weir L, Speers C, D'yachkova Y, Olivotto I: Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002;20: 1793-1799.
39. Clarke EA, Marrett LD, Kreiger N: Cancer registration in Ontario: A computer approach. IARC Sci Publ 1995;95(App 3ac):246-257.
40. Pinfold SP, Goel V, Sawka C: Quality of hospital discharge and physician data for type of breast cancer surgery. Med Care 2000; 38:99-107.
41. Chaudhry R, Goel V, Sawka C: Breast cancer survival by teaching status of the initial treating hospital. Can Med Assoc J 2001;164: 183-188.
42. Winchester DP, Cox JD: Standards of diagnosis and management of invasive breast cancer. CA 1998;48:83-107.
43. Southwest Oncology Group: Phase III Intergroup randomized trial of post-mastectomy radiotherapy in Stage II breast cancer in women with one to three positive axillary lymph nodes, S9927. www.swog.org.
44. National Cancer Institute of Canada-Clinical Trials Group. Phase III randomized study of adjuvant breast radiotherapy with or without regional radiotherapy in women with resected, early stage, invasive breast cancer, NCIC-CTG MA.20. www.cancer.gov/clinical_trials, 2000, accessed 2002.
45. Morrow M, Evans J, Rosen PP: Does the clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma? Cancer 1984;53:1329-1332.
46. Blair SL, O'Shea KE, Orr RK: Surgeon variability in treating nonpalpable breast cancer: Surgical oncology as a value-added specialty. Ann Surg Oncol 1998;5:28-32.
47. Sainsbury R, Rider L, Smith A, MacAdam A: Does it matter where you live? Treatment variation for breast cancer in Yorkshire. Br J Cancer 1995;71:1275-1278.
48. Porter GA, Soskolne CL, Yakimets WW, Newman SC: Surgeon-related factors and outcome in rectal cancer. Ann Surg 1998;227: 157-167.
49. Chaudhry R: Breast cancer survival by teaching status of the initial treating hospital. Toronto, Canada: University of Toronto, 1999.
50. Turner RR, Ollila DW, Krasne DL, Giuliano AE: Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-276; discussion 276-278.
51. Guenther JM: Axillary dissection after unsuccessful sentinel lymphadenectomy for breast cancer. Am Surg 1999;65:991-994.